Paul R Edick
CIK 1531178 · See Remarks · last filed 2025-11-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$25.95M
Companies
9
Total Filings
51
Lifetime Open-Market Net
$1.37M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VTGN | Director | — | $0.58 | — | $0 | 1 | 2025-11-04 |
| XERS | See Remarks | 3,821,494 | $6.79 | $25.95M | $1.30M | 19 | 2024-01-31 |
| MIST | Director | — | $1.27 | — | $0 | 1 | 2020-06-08 |
| Iterum Therapeutics plc (ITRM) Delisted | Director | 31,390 | $0.03 | $942 | $5.2K | 4 | 2019-05-29 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | Director | 214,563 | — | — | $0 | 4 | 2018-06-12 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Director | 0 | — | — | $0 | 4 | 2018-02-13 |
| Neos Therapeutics, Inc. (NEOS) Delisted | Director | — | $1.15 | — | $0 | 2 | 2017-07-05 |
| LUMOS PHARMA, INC. (NLNK) Delisted | Director | 7,906 | — | — | $0 | 10 | 2017-05-16 |
| Durata Therapeutics, Inc. (DRTX) Delisted | Chief Executive Officer | 24,636 | — | — | $64.5K | 5 | 2014-11-18 |
Recent Filings · Page 5 of 6
51 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-05-04 | LUMOS PHARMA, INC. (NLNK) Delisted | Grant (A) | +1,962 | $0 | EDGAR |
| 2014-11-18 | Durata Therapeutics, Inc. (DRTX) Delisted | Disp (D) | −46,136 | $0 | EDGAR |
| 2014-01-06 | LUMOS PHARMA, INC. (NLNK) Delisted | Grant (A) | +3,000 | $0 | EDGAR |
| 2013-05-20 | Durata Therapeutics, Inc. (DRTX) Delisted | Buy (P) | +3,000 | $21.3K | EDGAR |
| 2013-05-10 | LUMOS PHARMA, INC. (NLNK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-02-14 | Durata Therapeutics, Inc. (DRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-11-06 | LUMOS PHARMA, INC. (NLNK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-08-16 | Durata Therapeutics, Inc. (DRTX) Delisted | Buy (P) | +5,000 | $43.2K | EDGAR |
| 2012-07-26 | Durata Therapeutics, Inc. (DRTX) Delisted | Mixed | +19,636 | $0 | EDGAR |
| 2012-01-23 | LUMOS PHARMA, INC. (NLNK) Delisted | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.